Whole-genome CRISPR-Cas9 knockout screens identify SHOC2 as a genetic dependency in NRAS-mutant melanoma

Andrea Y. Gu; Tet Woo Lee; Aziza Khan; Xuenan Zhang; Francis W. Hunter; Dean C. Singleton; Stephen M. F. Jamieson

doi:10.1002/cac2.70013

Cancer Communications ›› 2025, Vol. 45 ›› Issue (6) :709 -713. DOI: 10.1002/cac2.70013

LETTER TO THE JOURNAL

Whole-genome CRISPR-Cas9 knockout screens identify SHOC2 as a genetic dependency in NRAS-mutant melanoma

Author information +

History +

PDF

Cite this article

Download citation ▾

Andrea Y. Gu, Tet Woo Lee, Aziza Khan, Xuenan Zhang, Francis W. Hunter, Dean C. Singleton, Stephen M. F. Jamieson. Whole-genome CRISPR-Cas9 knockout screens identify SHOC2 as a genetic dependency in NRAS-mutant melanoma. Cancer Communications, 2025, 45(6): 709-713 DOI:10.1002/cac2.70013

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32(25): 3009-3018.

[2]	Jakob JA, Bassett RL,, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al., NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118(16): 4014-4023.

[3]	Osrodek M, Hartman ML, Czyz M. Physiologically Relevant Oxygen Concentration (6% O(2)) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro. Int J Mol Sci. 2019; 20(17): 4203.

[4]	Tran KB, Gimenez G, Tsai P, Kolekar S, Rodger EJ, Chatterjee A, et al., Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma. Pigment Cell Melanoma Res. 2021; 34: 136-143.

[5]	Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol. 2014; 10(7): 733.

[6]	Jones GG, Del Rio IB, Sari S, Sekerim A, Young LC, Hartig N, et al. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat Commun. 2019; 10(1): 2532.

[7]	Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep. 2019; 29(1): 118-134 e8.

[8]	Lee TW, Hunter FW, Tsai P, Print CG, Wilson WR, Jamieson SMF. Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screens. Cancer Gene Ther. 2023; 30: 1610-1623.

[9]	Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell. 2006; 22(2): 217-230.